Objectives: Postmastectomy pain syndrome is a neuropathic pain syndrome that is known to develop after breast surgery. Preemptive analgesia has been shown to be efficacious in reducing postoperative pain, and may be effective in reducing the incidence of certain types of neuropathic pain. We investigated the analgesic efficacy of Venlafaxine and gabapentin on acute and chronic pain associated with cancer breast surgery.
M
odified radical mastectomy or lumpectomy with axillary node dissection, combined variably with chemotherapy or radiotherapy, is currently the treatment of choice for breast cancer. However, postoperative pain may be followed by chronic neuropathic pain, particularly after dissection of axillary lymph nodes and injury of the brachial plexus. In fact, postoperative pain may influence the development of chronic postmastectomy pain. 1 Postmastectomy pain syndrome (PMPS) is a neuropathic pain syndrome that is known to develop after breast surgery. This pain that affects the anterior thorax, axilla, or medial upper arm, is often burning, constant, and persistent and can be associated with allodynia or sensory loss. 2 A substantial number of women who undergo surgery for breast cancer develop chronic pain, and estimates of its incidence have ranged from 20% to 50% and higher. 3 If poorly treated, patients may develop an immobilized arm, which can lead to severe lymphedema, frozen shoulder syndrome, and complex regional pain syndrome. Pharmacologic therapy remains the initial treatment for PMPS. 4 Preemptive analgesia has been shown to be efficacious in reducing postoperative pain, 5 and may be effective in reducing the incidence of certain types of neuropathic pain. 6 The anticonvulsant gabapentin is widely used for treatment of chronic pain. 7 Venlafaxine hydrochloride is an antidepressant medication that, like tricyclic antidepressant inhibits the neuronal reuptake of both serotonin and norepinephrine. Venlafaxine does not bind to muscarniccholinergic, histaminc, and a 1 -adrenergic sites, making its side effects less severe than those of tricyclic antidepressant. 8 We investigated the analgesic efficacy of venlafaxine and gabapentin on acute and chronic pain associated with cancer breast surgery.
PATIENTS AND METHODS
After approval by the hospital ethics committee and a written informed consent, the study was carried out on 150 patients scheduled for either partial or radical mastectomy with axillary dissection. They were randomized to receive, in a double-blinded manner, venlafaxine extended release 37.5 mg/d, gabapentin 300 mg/d, or placebo for 10 days starting the night before operation.
The day before surgery, all patients were visited for assessment and to explain study protocols, including analgesic administration on request and the visual analog scale (VAS) score of pain severity at rest and after movement. Exclusion criteria included ASA physical status more than II; patients taking antidepressant or anticonvulsant medications, nonsteroidal antiinflammatory drugs, or opioid analgesics; patients with hepatic or renal impairment, history of diabetes, or other neuropathic disease; or allergies for any used drugs.
A prospective, randomized (sealed envelopes indicate the group of assignment), double-blind design was used, with both patients and postoperative assessors blinded to management protocol. An independent anesthesiologist, who did not participate in the study or data collection, read the number contained in the envelope and made group assignments. Control (sugar filled) and/or treatment capsules for each group were packaged in group-specific bottles and coded as Bottle 1, Bottle 2, and Bottle 3 for Groups 1, 2, and 3, respectively. Yellow hard gelatin capsules (identical in appearance to the gabapentin capsules) and gray/peach capsules (identical in appearance to the venlafaxine extended release capsules) were filled with thin sugar. Envelopes, bottles with capsules, and coding were prepared by the pharmacy of the hospital.
Patients were blindly randomized to 1 of 3 groups, 50 in each group, the process of inclusion into the study went on until the requested number of patients was reached. In the (Group 1) venlafaxine group, patients received 37.5 mg of venlafaxine extended release along with another capsule (identical in appearance to the gabapentin capsules) once daily at bed time. Patients in the (Group 2) gabapentin group received 300 mg of gabapentin and another capsule (identical in appearance to the venlafaxine extended release capsules) once daily at bed time. Patients in the (Group 3) placebo group received 2 capsules that were filled with thin sugar (1 identical in appearance to the gabapentin capsules and the other identical to venlafaxine extended release capsules) once daily at bed time. Administration of the drugs started the evening before surgery and continued for the first 10 postoperative days, including the day of the surgery.
Anesthesia was standardized, after preoxygenation for 3 to 4 minutes, anesthesia was induced with thiopental 3 to 5 mg/kg and fentanyl 1 to 2 mg/kg. Intubation of the trachea was facilitated with rocuronium 0.6 mg/kg, anesthesia was maintained with 1% to 2% isoflurane, 70% nitrous oxide in oxygen, and incremental rocuronium doses were repeated to maintain neuromuscular block. At the end of surgery, neuromuscular block was antagonized with neostigmine 2.5 mg and atropine 1 mg.
After tracheal extubation, patients were transferred to the recovery room. When patients complained of pain in the recovery room, they received a titrated dose of morphine (2 mg bolus at 5 min intervals) until the VAS was less than or equal to 30, and then i.v. morphine 20 to 50 mcg/kg was given as necessary to relieve severe pain, rated by using VAS greater than 30 for the first 24 hours after surgery, and then, acetaminophen/codeine tablets from the second to the tenth postoperative day, the patients were administered (acetaminophen 500 mg/codeine 30 mg tablets, Feminax-Bayer) 1 tablet every 6 hours or as necessary.
Pain scores were recorded at rest and movement (VAS) at 4, 12, 24 hours on the first day postoperatively, daily from the second to the tenth day postoperatively, and 6 months later. Movement consisted of abduction of the arm on the operated side by 90 degrees. Patients were invited to a pain evaluation 6 months later. In addition, they were requested to complete a short questionnaire (Table 1 ). Patients were informed that they had the option of discontinuing participation in the study at any time.
The sample size selected was on the basis of hypothesis that gabapentin reduces the need for opioids for postoperative pain treatment. We calculated that we would need 34 patients per group to have an 80% chance of detecting a 35% reduction in 24-hour morphine consumption at a 5% significance level, using a Mann-Whitney test with a 0.05 2-sided significance level (nQuery Advisor, Version 5.0). Standard deviations (SD) estimated from initial pilot observations were approximately 6 mg for intravenous morphine in recovery room and 19.5 mg for total morphine consumption in the ward in the first 24 hours.To enable detection of potential differences in the side-effects between the 2 groups, we expected that somewhat larger groups would be required, and 50 patients per group included.
Statistical Analysis
Data were analyzed using SPSS 15.0 software, with Fisher exact test, unpaired t-test, and Mann-Whitney test, as appropriate; P<0.05 was considered to be statistically significant.
RESULTS
The groups that received venlafaxine, gabapentin, or placebo were similar with regard to age (45 ± 6 y, 43 ± 5 y, and 44 ± 8 y, respectively), body weight (83 ± 6 kg, 85 ± 5 kg, and 81 ± 6 kg, respectively), and height (160 ± 4 cm, 158 ± 5 cm, and 159 ± 6 cm, respectively). Values are mean ± SD. There was no significant difference between groups regarding duration of surgery, patients treated with chemotherapy, and/or radiotherapy ( Table 2) .
The VAS scores ( Fig. 1 ) after movement were similar during the first 24 hours. The VAS score after movement was significantly reduced in the gabapentin group from the second (P = 0.0003), third to the tenth day (P<0.0001), for gabapentin versus control group for all individual comparisons. Also the VAS score after movement was significantly reduced in the venlafaxine group in the eighth, (P = 0.0002) ninth, and tenth days postoperatively (P<0.0001) in comparison with the control group. The VAS scores (Fig. 2) at rest did not differ among the groups during the first 10 postoperative days.
There was significant decrease in the analgesic requirement in the recovery room in gabapentin group (P<0.0001), intravenous morphine in recovery (mean ± SD mg) was 7 ± 0.5, 4.5 ± 0.5, and 7 ± 1.1 in the venlafaxine, gabapentin, and control group, respectively. Time to first requested analgesic in ward (mean ± SD) was 105 ± 15 minute, 155 ± 17 minute, and 100 ± 12 minute in the venlafaxine, gabapentin, and control group, respectively, and there was significant delay in the gabapentin group than the others (compared with the other 2 groups P<0.0001).
The total morphine consumption in ward in the first 24 hours was significantly reduced in gabapentin group (P<0.0001 compared with the other 2 groups) mean ± SD (mg), 21 ± 1.5, 13.5 ± 0.5, and 22 ± 2.1 in the venlafaxine, gabapentin, and control group, respectively. Codeine and paracetamol consumption given orally from the second to the tenth day were significantly reduced in the venlafaxine and gabapentin groups compared to the control group (P<0.0001), mean ± SD (mg) for paracetamol (3305 ± 2166, 3105 ± 1998, 5216 ± 2320 respectively), mean ± SD (mg) for codeine (185 ± 54, 180 ± 22, 300 ± 156 respectively).
There were no differences in side-effects between the 2 groups. About half of the patients complained of nausea and about one-third had vomiting during the 24-hour postoperative period. Drowsiness and dizziness were more common in the gabapentin and venlafaxine groups than in the placebo group, but this was not significant. There was no difference in the length of hospital stay. Pain scores with movement at 6 months were significantly higher in the control and gabapentin groups compared with the venlafaxine group P<0.0001 (22 ± 9, 21 ± 12, 12 ± 5), respectively.
Incidence of burning pain was significantly decreased in the venalafaxine group in comparison with the control group (P = 0.0018) ( Table 3) . Although burning was more frequent in control group, however, there was no significant difference in comparison with gabapentin group P = 0.143. In addition, stabbing or pricking was significantly reduced in venlafaxine group in comparison with the control and gabapentin groups (P = 0.003 and 0.028 respectively). There was no significant difference regarding other types of pain. Significantly more patients in the control (P = 0.02) and gapapentin (P = 0.03) groups were using opioid analgesics for pain management at 6 months postoperatively compared with the venlafaxine group (18, 17, 8, respectively) .
DISCUSSION
The results of this study indicate that gabapentin decreased pain scores at movement, morphine, and analgesic consumption in the acute phase but had no significant effect on the incidence of chronic pain except lower incidence of burning pain sensations 6 months later.
Sensitization of neurones in the dorsal horns, a mechanism in neuropathic pain, has been shown in acute pain models. 5 The persistence of this mechanism may be responsible for the increasingly recognized problem of chronic pain after surgery. 9 Gabapentin has a high binding affinity for the a 2 d subunit of the presynaptic voltage-gated calcium channels 10 that inhibit calcium influx and subsequent release of excitatory neurotransmitters in the pain pathways.
The analgesic efficacy of gabapentin used preemptively has been shown in surgical patients. Dirks et al 7 gave a single oral dose of 1200 mg of gabapentin to patients undergoing radical mastectomy. They found a substantial reduction in the postoperative morphine consumption without significant side effects. Combined data from other control randomized trials 11, 12 showed lower pain scores at rest in the gabapentin group in the late postoperative period at 24 hours. Reduction of pain after movement, a more consistent finding in the gabapentin group, is important because immobilization of the arm to avoid pain may result in its ankylosis and an inability of the patient to work.
Gabapentin had no effect on pain transmission in normal skin but significantly reduced hyperalgesia after an experimental thermal injury or heat capsaicin sensitization. 13 The pattern of activity is of considerable importance in that, gabapentin may reduce pathologic pain, whereby leaving other protective nociceptive mechanisms intact. 14 Animal studies have shown that although gabapentin does not affect the nociceptive threshold, it is effective in reducing both allodynia and hyperalgesia, suggesting that it has a selective effect on the nociceptive process involved in central sensitization. 14, 15 Contrary to our results regarding acute pain, gabapentin had no analgesic effect on its own when given as a single oral dose of 600 mg in volunteers, although it enhances the analgesic effect of morphine. 16 A single dose of 300 mg of the drug given 1 hour before laparoscopic cholecystectomy failed to attenuate acute postoperative pain. 17 In addition, oral preoperative administration of gabapentin did not modify immediate pain management in thyroidectomy patients receiving SCPB (superficial cervical plexus block), but prevented delayed neuropathic pain at 6 months. 18 However, Al-Mujadi et al, 19 concluded that preoperative gabapentin decreased pain scores and postoperative morphine consumption in patients after thyroid surgery. The dose of gabapentin at 300 mg may have been too low to produce an effect at 6 months in our study. However, Seok et al 20 concluded that gabapentin has a preemptive effect in gynecologic surgery, but there were no additional fentanyl-sparing benefits at doses above 300 mg. Thus, 300 mg is an optimal dose for decreasing fentanyl consumption after gynecologic surgery.
The limitations of our study are that the sample size selection on the basis of changes in acute pain so the sample size we studied may be too small for the chronic pain statistical evaluation. However, we depend on the hypothesis that, adequate treatment of acute postoperative pain may be associated with better control of chronic pain; we based the sample size estimation on the results obtained from the acute pain.
A common psychopharmacology between pain and depression suggests that compounds inhibiting the reuptake of serotonin and/or noradrenaline are likely to produce relief from chronic pain. 21 Our results show that the perioperative administration of venlafaxine extended release 37.5 beginning the night before surgery, had no analgesic effect on the first postoperative day, the effect seemed clinically at the last 3 days postoperatively and with no effect on morphine consumption on the first day but analgesic use significantly reduced from the second to tenth day. The incidence of PMPS and analgesic use significantly decreased at 6 months. Venlafaxine is of particular interest for 2 reasons, (1) it is broad neurotransmitter profile similar to the tricyclic group and has led to speculation that it may have promise as an analgesic and, 4 (2) it is similar in structure to tramadol, an analgesic with both opioid agonist and monoaminergic activity. 22 Songer and Schulte 23 in the first reported case discussing venlafaxine as an analgesic, described a patient with radicular back pain started venlafaxine at a dose of 37.5 twice daily and within 3 days the back pain of the patient markedly decreased. Taylor Although there are specific plasma concentrations of antidepressant medications in human beings that correlate with effective antidepressant activity, markedly lower doses and concentrations have been found to be effective in treating chronic pain. 24 In the rat model of neuropathic pain, 25 venlafaxine produced significant analgesia despite low blood concentrations.
The reason for the similarity in pain scores between the control and venlafaxine groups may have reflected the greater postoperative use of analgesia in the first 10 postoperative days in the control group compared with the venlafaxine group. Pernia et al, 26 administered venlafaxine 37.5 mg twice daily with the piroxicam in female patient with postspinal fixation neuropathic pain. After 7 days of treatment, the patient reported considerable symptomatic relief, with a maximum level of pain of 35 on the VAS.
Simpson 27 designed a study to test gabapentin plus venlafaxine in comparison with gabapentin plus placebo in 11 patients with painful diabetic neuropathy. They evaluated pain reduction and improvement in quality of life and mood disturbance, and suggested using this combination for the treatment of neuropathic pain patients but the combination of the 2 drugs in postoperative pain have not been tried.
CONCLUSION
Venlafaxine 37.5 mg/d extended release or gabapentin 300 mg/d have equipotent effects (except the first day in venlafaxine group) in reducing analgesic requirements, although gabapentin is more effective in reducing pain after movement. Venlafaxine significantly reduced the incidence of postmastectomy pain syndromes (chronic pain) for 6 months in women having breast cancer surgery. Gabapentin had no effect on chronic pain except decreasing incidence of burning pain.
